Novartis Ag (NVS) Notes Payables (2016 - 2025)
Novartis Ag (NVS) posted Notes Payables of $682.0 million for Q4 2025, up 6.23% sequentially from $642.0 million in Q4 2024, and up 6.23% YoY from $642.0 million in Q4 2024.
Novartis Ag (NVS) Notes Payables (2016 - 2025) Analysis & Trends
Novartis Ag has reported Notes Payables for 10 years, with the latest figure at $682.0 million in Q4 2025.
- Quarterly Notes Payables rose 6.23% year-over-year to $682.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $682.0 million (up 6.23% YoY) and the FY2025 annual result came in at $682.0 million, up 6.23% from the prior year.
- Notes Payables advanced to $682.0 million in Q4 2025 per NVS's latest filing, from $642.0 million in the prior quarter.
- Over five years, Notes Payables peaked at $899.0 million in Q4 2021 and troughed at $624.0 million in Q4 2023.
- A 5-year average of $742.0 million and a median of $682.0 million in 2025 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2023 and 2025: Notes Payables fell 27.69% in 2023, then climbed 6.23% in 2025.
- Over 5 years, Notes Payables stood at $899.0 million in 2021, then declined by 4.0% to $863.0 million in 2022, then declined by 27.69% to $624.0 million in 2023, then advanced by 2.88% to $642.0 million in 2024, then grew by 6.23% to $682.0 million in 2025.
- According to Business Quant data, Notes Payables over the past three periods registered $682.0 million, $642.0 million, and $624.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 682.00 Mn |
| Dec 31, 2024 | 642.00 Mn |
| Dec 31, 2023 | 624.00 Mn |
| Dec 31, 2022 | 863.00 Mn |
| Dec 31, 2021 | 899.00 Mn |
| Dec 31, 2020 | 976.00 Mn |
| Dec 31, 2019 | 719.00 Mn |
| Dec 31, 2018 | 701.00 Mn |
| Dec 31, 2017 | 692.00 Mn |
| Dec 31, 2016 | 836.00 Mn |